NASDAQ: CADL - Candel Therapeutics, Inc.

Rentabilidade por seis meses: +29.08%
Setor: Healthcare

Cronograma de promoção Candel Therapeutics, Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma.

Mais detalhes
It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is based in Needham, Massachusetts.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

Цена ао 1.49
Выручка 0.000125
EBITDA -0.0076
P/S 1829.26
P/BV 3.57
EV/EBITDA 0.6279
ISIN US1374041093
Сайт https://www.candeltx.com
Число акций ао 0.02894 млрд
Валюта usd
IPO date 2021-07-27
Sector Health Care
Industry Biotechnology
Валюта отчета usd
Alteração de preço por dia: -2.09% (6.71)
Alteração de preço por semana: -8.88% (7.21)
Alteração de preço por mês: +4.12% (6.31)
Alteração de preço em 3 meses: +13.67% (5.78)
Mudança de preço em seis meses: +29.08% (5.09)
Mudança de preço por ano: +606.45% (0.93)
Mudança de preço em 3 anos: -33.84% (9.93)
Mudança de preço desde o início do ano: +614.13% (0.92)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 1064.07 1
P/BV 2.59 6
P/E 0 0
EV/EBITDA -0.5468 0
Total: 3.5

Eficiência

Nome Significado Nota
ROA, % -90.98 0
ROE, % -297.68 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.5859 10
Total: 9.8

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % -75.2 0
Rentabilidade Ebitda, % 389.36 10
Rentabilidade EPS, % 205.63 10
Total: 8
Mais detalhes

Instituições Volume Compartilhar, %
Northpond Ventures, Llc 1935215 6.59
Sands Capital Ventures, LLC 811737 2.77
Vanguard Group Inc 425749 1.45
FMR, LLC 298384 1.02
Geode Capital Management, LLC 139253 0.47
Bridgeway Capital Management, Inc. 132595 0.45
Baystate Wealth Management LLC 76910 0.26
Blackrock Inc. 49285 0.17
OneDigital Investment Advisors LLC 29783 0.1
State Street Corporation 27600 0.09

ETF Compartilhar, % Rentabilidade para o ano, % Dividendos, %
ProShares Hedge Replication ETF 0.00093 5.9237999659878 1.47892
iShares Micro-Cap ETF 0.03787 36.318555985322 1.54048
iShares Russell 2000 Growth ETF 0.01119 38.042556988 0.6026
ProShares UltraPro Russell2000 0.00323 89.821266282945 1.47873
Vanguard Russell 3000 ETF 0 31.87314172448 1.43817
Vanguard Russell 2000 Growth ETF 0.01 39.350070246167 0.60264
Vanguard Russell 2000 ETF 0 35.648084105685 1.48801



Supervisor Cargo Pagamento Ano de nascimento
Dr. Seshu Tyagarajan Ph.D. Chief Technical & Development Officer 335.27k 1968 (56 anos)
Dr. Francesca Barone M.D., Ph.D. Chief Scientific Officer 506.76k 1978 (46 anos)
Ms. Ileen B. Winick Chief People Officer N/A
Ms. Susan Stewart J.D., L.L.M. Chief Regulatory Officer N/A 1961 (63 ano)
Dr. William Garrett Nichols M.D., M.S. Chief Medical Officer N/A 1969 (55 anos)
Mr. Charles Schoch Interim CFO, Principal Accounting Officer, Treasurer & Secretary N/A 1985 (39 anos)
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D. President, CEO & Director 1961 (63 ano)

Endereço: United States, Needham. MA, 117 Kendrick Street - abrir no Google Maps, abrir mapas Yandex
Site: https://www.candeltx.com